{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:52:33Z","timestamp":1794351153932,"version":"4.9.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI173059"],"award-info":[{"award-number":["R01AI173059"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI125704"],"award-info":[{"award-number":["R01AI125704"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI056493"],"award-info":[{"award-number":["U01AI056493"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM151334"],"award-info":[{"award-number":["R01GM151334"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fast-acting botulinum neurotoxins (BoNTs) are highly desirable for both medical and aesthetic indications, but the underlying mechanism for the differing onset of BoNTs\u2019 action remains unknown. Here, we demonstrate that the \u201cbelt\u201d of BoNTs, a largely unstructured loop wrapping around their catalytic light chain (LC), is key to onset of intoxication. The more flexible BoNT\/E belt promotes quicker LC translocation into the neuronal cytosol, leading to faster onset of action compared to BoNT\/A. Furthermore, we discover a \u201cbelt-buckle\u201d checkpoint that regulates this process. By loosening the BoNT\/A belt-buckle via protein engineering, we enhance its sensitivity to acidic pH, leading to an accelerated onset of action. Conversely, locking the belt-buckle with an antibody neutralizes BoNT\/A. Our findings open avenues for developing fast-acting BoNTs and effective countermeasures.<\/jats:p>","DOI":"10.1038\/s41467-026-74499-7","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:55:10Z","timestamp":1782233710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A belt-buckle checkpoint regulates the onset of botulinum neurotoxin intoxication"],"prefix":"10.1038","volume":"17","author":[{"given":"Baohua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-5145","authenticated-orcid":false,"given":"Linfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"B\u00f6nninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-501X","authenticated-orcid":false,"given":"Nadja","family":"Krez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9525-6986","authenticated-orcid":false,"given":"Mark","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlong","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-1641","authenticated-orcid":false,"given":"Andreas","family":"Rummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-7363","authenticated-orcid":false,"given":"Rongsheng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"74499_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrmicro3295","volume":"12","author":"O Rossetto","year":"2014","unstructured":"Rossetto, O., Pirazzini, M. & Montecucco, C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat. Rev. Microbiol 12, 535\u2013549 (2014).","journal-title":"Nat. Rev. Microbiol"},{"key":"74499_CR2","first-page":"3233","volume":"125","author":"L Peng","year":"2012","unstructured":"Peng, L. et al. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J. Cell Sci. 125, 3233\u20133242 (2012).","journal-title":"J. Cell Sci."},{"key":"74499_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.febslet.2011.12.037","volume":"586","author":"J Strotmeier","year":"2012","unstructured":"Strotmeier, J., Willjes, G., Binz, T. & Rummel, A. Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett. 586, 310\u2013313 (2012).","journal-title":"FEBS Lett."},{"key":"74499_CR4","doi-asserted-by":"publisher","first-page":"116516","DOI":"10.1016\/j.jns.2019.116516","volume":"407","author":"L Pons","year":"2019","unstructured":"Pons, L., Vilain, C., Volteau, M. & Picaut, P. Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport(R)). J. Neurol. Sci. 407, 116516 (2019).","journal-title":"J. Neurol. Sci."},{"key":"74499_CR5","doi-asserted-by":"publisher","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","volume":"142","author":"SG Yoelin","year":"2018","unstructured":"Yoelin, S. G. et al. Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study. Plast. Reconstr. Surg. 142, 847e\u2013855e (2018).","journal-title":"Plast. Reconstr. Surg."},{"key":"74499_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1021\/bi0356698","volume":"43","author":"JE Keller","year":"2004","unstructured":"Keller, J. E., Cai, F. & Neale, E. A. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43, 526\u2013532 (2004).","journal-title":"Biochemistry"},{"key":"74499_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0304-3940(98)00775-7","volume":"256","author":"R Eleopra","year":"1998","unstructured":"Eleopra, R., Tugnoli, V., Rossetto, O., De Grandis, D. & Montecucco, C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci. Lett. 256, 135\u2013138 (1998).","journal-title":"Neurosci. Lett."},{"key":"74499_CR8","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1074\/jbc.M209821200","volume":"278","author":"PG Foran","year":"2003","unstructured":"Foran, P. G. et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 278, 1363\u20131371 (2003).","journal-title":"J. Biol. Chem."},{"key":"74499_CR9","doi-asserted-by":"publisher","first-page":"16993","DOI":"10.1074\/jbc.M710442200","volume":"283","author":"J Wang","year":"2008","unstructured":"Wang, J. et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J. Biol. Chem. 283, 16993\u201317002 (2008).","journal-title":"J. Biol. Chem."},{"key":"74499_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jaad.2023.08.072","volume":"89","author":"M Alam","year":"2023","unstructured":"Alam, M. et al. Botulinum toxin type E associated with reduced itch and pain during wound healing and acute scar formation following excision and linear repair on the forehead: a randomized controlled trial. J. Am. Acad. Dermatol. 89, 1317\u20131319 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"74499_CR11","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-022-10995-2","volume":"269","author":"C Ledda","year":"2022","unstructured":"Ledda, C. et al. Time to onset and duration of botulinum toxin efficacy in movement disorders. J. Neurol. 269, 3706\u20133712 (2022).","journal-title":"J. Neurol."},{"key":"74499_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/0968-0004(86)90282-3","volume":"11","author":"C Montecucco","year":"1986","unstructured":"Montecucco, C. How do tetanus and botulinum neurotoxins bind to neuronal membranes? Trends Biochem. Sci. 11, 314\u2013317 (1986).","journal-title":"Trends Biochem. Sci."},{"key":"74499_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tim.2004.08.002","volume":"12","author":"C Montecucco","year":"2004","unstructured":"Montecucco, C., Rossetto, O. & Schiavo, G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 12, 442\u2013446 (2004).","journal-title":"Trends Microbiol."},{"key":"74499_CR14","first-page":"61","volume":"364","author":"A Rummel","year":"2013","unstructured":"Rummel, A. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr. Top. Microbiol. Immunol. 364, 61\u201390 (2013).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"74499_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pbiomolbio.2015.02.004","volume":"117","author":"KH Lam","year":"2015","unstructured":"Lam, K. H., Yao, G. & Jin, R. Diverse binding modes, same goal: the receptor recognition mechanism of botulinum neurotoxin. Prog. Biophys. Mol. Biol. 117, 225\u2013231 (2015).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"74499_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/359832a0","volume":"359","author":"G Schiavo","year":"1992","unstructured":"Schiavo, G. et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832\u2013835 (1992).","journal-title":"Nature"},{"key":"74499_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/365160a0","volume":"365","author":"J Blasi","year":"1993","unstructured":"Blasi, J. et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365, 160\u2013163 (1993).","journal-title":"Nature"},{"key":"74499_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1017\/S0033583500003292","volume":"28","author":"C Montecucco","year":"1995","unstructured":"Montecucco, C. & Schiavo, G. Structure and function of tetanus and botulinum neurotoxins. Q Rev. Biophys. 28, 423\u2013472 (1995).","journal-title":"Q Rev. Biophys."},{"key":"74499_CR19","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1091\/mbc.e08-07-0765","volume":"19","author":"M Dong","year":"2008","unstructured":"Dong, M. et al. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell 19, 5226\u20135237 (2008).","journal-title":"Mol. Biol. Cell"},{"key":"74499_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1042\/BJ20130391","volume":"453","author":"S Mahrhold","year":"2013","unstructured":"Mahrhold, S. et al. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J. 453, 37\u201347 (2013).","journal-title":"Biochem J."},{"key":"74499_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1123654","volume":"312","author":"M Dong","year":"2006","unstructured":"Dong, M. et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592\u2013596 (2006).","journal-title":"Science"},{"key":"74499_CR22","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.febslet.2006.02.074","volume":"580","author":"S Mahrhold","year":"2006","unstructured":"Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. & Binz, T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580, 2011\u20132014 (2006).","journal-title":"FEBS Lett."},{"key":"74499_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37860-8","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2. Nat. Commun. 14, 2338 (2023).","journal-title":"Nat. Commun."},{"key":"74499_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nsmb.3245","volume":"23","author":"G Yao","year":"2016","unstructured":"Yao, G. et al. N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Nat. Struct. Mol. Biol. 23, 656\u2013662 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"74499_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12732","volume":"505","author":"RM Benoit","year":"2014","unstructured":"Benoit, R. M. et al. Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature 505, 108\u2013111 (2014).","journal-title":"Nature"},{"key":"74499_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56304-z","volume":"16","author":"B Khanppnavar","year":"2025","unstructured":"Khanppnavar, B., Leka, O., Pal, S. K., Korkhov, V. M. & Kammerer, R. A. Cryo-EM structure of the botulinum neurotoxin A\/SV2B complex and its implications for translocation. Nat. Commun. 16, 1224 (2025).","journal-title":"Nat. Commun."},{"key":"74499_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/2338","volume":"5","author":"DB Lacy","year":"1998","unstructured":"Lacy, D. B., Tepp, W., Cohen, A. C., DasGupta, B. R. & Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5, 898\u2013902 (1998).","journal-title":"Nat. Struct. Biol."},{"key":"74499_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/78005","volume":"7","author":"S Swaminathan","year":"2000","unstructured":"Swaminathan, S. & Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7, 693\u2013699 (2000).","journal-title":"Nat. Struct. Biol."},{"key":"74499_CR29","doi-asserted-by":"crossref","unstructured":"Kosenina, S., Martinez-Carranza, M., Davies, J. R., Masuyer, G. & Stenmark, P. Structural analysis of botulinum neurotoxins type B and E by cryo-EM. Toxins 14, 14 (2021).","DOI":"10.3390\/toxins14010014"},{"key":"74499_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jmb.2008.12.027","volume":"386","author":"D Kumaran","year":"2009","unstructured":"Kumaran, D. et al. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 386, 233\u2013245 (2009).","journal-title":"J. Mol. Biol."},{"key":"74499_CR31","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1371\/journal.ppat.0030113","volume":"3","author":"AT Brunger","year":"2007","unstructured":"Brunger, A. T. et al. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 3, 1191\u20131194 (2007).","journal-title":"PLoS Pathog."},{"key":"74499_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/protein\/gzq001","volume":"23","author":"J Lou","year":"2010","unstructured":"Lou, J. et al. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng. Des. Sel. 23, 311\u2013319 (2010).","journal-title":"Protein Eng. Des. Sel."},{"key":"74499_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jmb.2006.09.084","volume":"365","author":"R Levy","year":"2007","unstructured":"Levy, R. et al. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J. Mol. Biol. 365, 196\u2013210 (2007).","journal-title":"J. Mol. Biol."},{"key":"74499_CR34","doi-asserted-by":"crossref","unstructured":"Lou, J. et al. A single tri-epitopic antibody virtually recapitulates the potency of a combination of three monoclonal antibodies in neutralization of botulinum neurotoxin serotype A. Toxins 10, 84 (2018).","DOI":"10.3390\/toxins10020084"},{"key":"74499_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ab.2011.09.030","volume":"421","author":"Q Meng","year":"2012","unstructured":"Meng, Q. et al. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal. Biochem. 421, 351\u2013361 (2012).","journal-title":"Anal. Biochem."},{"key":"74499_CR36","doi-asserted-by":"crossref","unstructured":"Lam, K. H., Perry, K., Shoemaker, C. B. & Jin, R. Two VHH antibodies neutralize botulinum neurotoxin E1 by blocking its membrane translocation in host cells. Toxins 12, 616 (2020).","DOI":"10.3390\/toxins12100616"},{"key":"74499_CR37","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.celrep.2020.01.107","volume":"30","author":"KH Lam","year":"2020","unstructured":"Lam, K. H. et al. Structural insights into rational design of single-domain antibody-based antitoxins against botulinum neurotoxins. Cell Rep. 30, 2526\u20132539.e6 (2020).","journal-title":"Cell Rep."},{"key":"74499_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jsb.2010.11.010","volume":"174","author":"G Masuyer","year":"2011","unstructured":"Masuyer, G., Beard, M., Cadd, V. A., Chaddock, J. A. & Acharya, K. R. Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B. J. Struct. Biol. 174, 52\u201357 (2011).","journal-title":"J. Struct. Biol."},{"key":"74499_CR39","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.15252\/embr.201744198","volume":"18","author":"G Masuyer","year":"2017","unstructured":"Masuyer, G., Conrad, J. & Stenmark, P. The structure of the tetanus toxin reveals pH-mediated domain dynamics. EMBO Rep. 18, 1306\u20131317 (2017).","journal-title":"EMBO Rep."},{"key":"74499_CR40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1126\/science.1214270","volume":"335","author":"S Gu","year":"2012","unstructured":"Gu, S. et al. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335, 977\u2013981 (2012).","journal-title":"Science"},{"key":"74499_CR41","doi-asserted-by":"publisher","first-page":"17795","DOI":"10.1038\/srep17795","volume":"5","author":"S Eswaramoorthy","year":"2015","unstructured":"Eswaramoorthy, S., Sun, J., Li, H., Singh, B. R. & Swaminathan, S. Molecular assembly of Clostridium botulinum progenitor M complex of type e. Sci. Rep. 5, 17795\u201317795 (2015).","journal-title":"Sci. Rep."},{"key":"74499_CR42","doi-asserted-by":"crossref","unstructured":"Gao, L. et al. Botulinum neurotoxins exploit host digestive proteases to boost their oral toxicity via activating OrfXs\/P47. Nat. Struct. Mol. Biol. 32, 864\u2013875 (2025).","DOI":"10.1038\/s41594-024-01479-0"},{"key":"74499_CR43","first-page":"21","volume":"364","author":"S Gu","year":"2013","unstructured":"Gu, S. & Jin, R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr. Top. Microbiol. Immunol. 364, 21\u201344 (2013).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"74499_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07789-4","volume":"9","author":"KH Lam","year":"2018","unstructured":"Lam, K. H. et al. A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1. Nat. Commun. 9, 5367 (2018).","journal-title":"Nat. Commun."},{"key":"74499_CR45","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.3390\/toxins7124861","volume":"7","author":"J Weisemann","year":"2015","unstructured":"Weisemann, J. et al. Generation and characterization of six recombinant botulinum neurotoxins as reference material to serve in an international proficiency test. Toxins 7, 5035\u20135054 (2015).","journal-title":"Toxins"},{"key":"74499_CR46","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.3390\/toxins7124855","volume":"7","author":"H Bigalke","year":"2015","unstructured":"Bigalke, H. & Rummel, A. Botulinum neurotoxins: qualitative and quantitative analysis using the mouse phrenic nerve hemidiaphragm assay (MPN). Toxins 7, 4895\u20134905 (2015).","journal-title":"Toxins"},{"key":"74499_CR47","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1111\/j.1471-4159.2009.06093.x","volume":"109","author":"T Binz","year":"2009","unstructured":"Binz, T. & Rummel, A. Cell entry strategy of clostridial neurotoxins. J. Neurochem. 109, 1584\u20131595 (2009).","journal-title":"J. Neurochem."},{"key":"74499_CR48","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/j.1471-4159.2009.06298.x","volume":"110","author":"A Rummel","year":"2009","unstructured":"Rummel, A. et al. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 110, 1942\u20131954 (2009).","journal-title":"J. Neurochem."},{"key":"74499_CR49","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.chembiol.2007.03.014","volume":"14","author":"NR Silvaggi","year":"2007","unstructured":"Silvaggi, N. R. et al. Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem. Biol. 14, 533\u2013542 (2007).","journal-title":"Chem. Biol."},{"key":"74499_CR50","doi-asserted-by":"publisher","first-page":"6888","DOI":"10.1073\/pnas.0400584101","volume":"101","author":"B Segelke","year":"2004","unstructured":"Segelke, B., Knapp, M., Kadkhodayan, S., Balhorn, R. & Rupp, B. Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: evidence for noncanonical zinc protease activity. Proc. Natl. Acad. Sci. USA 101, 6888\u20136893 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74499_CR51","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nature03123","volume":"432","author":"MA Breidenbach","year":"2004","unstructured":"Breidenbach, M. A. & Brunger, A. T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432, 925\u2013929 (2004).","journal-title":"Nature"},{"key":"74499_CR52","doi-asserted-by":"crossref","unstructured":"Tremblay, J. M. et al. Camelid VHH antibodies that neutralize botulinum neurotoxin serotype E intoxication or protease function. Toxins 12, 611 (2020).","DOI":"10.3390\/toxins12100611"},{"key":"74499_CR53","doi-asserted-by":"publisher","first-page":"e1010169","DOI":"10.1371\/journal.ppat.1010169","volume":"18","author":"KH Lam","year":"2022","unstructured":"Lam, K. H. et al. Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies. PLoS Pathog. 18, e1010169 (2022).","journal-title":"PLoS Pathog."},{"key":"74499_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nbt1269","volume":"25","author":"C Garcia-Rodriguez","year":"2007","unstructured":"Garcia-Rodriguez, C. et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat. Biotechnol. 25, 107\u2013116 (2007).","journal-title":"Nat. Biotechnol."},{"key":"74499_CR55","doi-asserted-by":"publisher","first-page":"11346","DOI":"10.1073\/pnas.172229899","volume":"99","author":"A Nowakowski","year":"2002","unstructured":"Nowakowski, A. et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99, 11346\u201311350 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74499_CR56","doi-asserted-by":"publisher","first-page":"8903","DOI":"10.1021\/bi060786z","volume":"45","author":"Z Fu","year":"2006","unstructured":"Fu, Z. et al. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry 45, 8903\u20138911 (2006).","journal-title":"Biochemistry"},{"key":"74499_CR57","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1021\/bi0157969","volume":"41","author":"T Binz","year":"2002","unstructured":"Binz, T., Bade, S., Rummel, A., Kollewe, A. & Alves, J. Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry 41, 1717\u20131723 (2002).","journal-title":"Biochemistry"},{"key":"74499_CR58","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"74499_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jsb.2005.07.007","volume":"152","author":"DN Mastronarde","year":"2005","unstructured":"Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36\u201351 (2005).","journal-title":"J. Struct. Biol."},{"key":"74499_CR60","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."},{"key":"74499_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"74499_CR62","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"74499_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"74499_CR64","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/j.1348-0421.2012.00490.x","volume":"56","author":"K Tsukamoto","year":"2012","unstructured":"Tsukamoto, K. et al. P19 embryonal carcinoma cells exhibit high sensitivity to botulinum type C and D\/C mosaic neurotoxins. Microbiol. Immunol. 56, 664\u2013672 (2012).","journal-title":"Microbiol. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74499-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74499-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74499-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T18:02:52Z","timestamp":1782237772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74499-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74499"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74499-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J. is a co-founder, shareholder, and consultant of Claruvis Biotech, a shareholder of MingMed Biotech, and the founder of J&Z Consulting. R.J.\u2018s relationship with these companies has been reviewed and approved by the University of California, Irvine, in accordance with its conflict of interest policies. A provisional patent application has been filed by The Regents of the University of California on fast-acting botulinum neurotoxins with R.J. and B.C. as inventors. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5562"}}